Edwards Lifesciences Corporation (NYSE:EW) Stock Has Consensus Target Price of $100.27 According to Brokerages

by · The Markets Daily

Shares of Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty-six brokerages that are presently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $100.27.

EW has been the topic of several research analyst reports. Robert W. Baird lowered their price objective on Edwards Lifesciences from $94.00 to $90.00 and set a “neutral” rating on the stock in a report on Thursday, October 15th. TD Cowen reissued a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Sanford C. Bernstein increased their target price on Edwards Lifesciences from $96.00 to $99.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Piper Sandler restated an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Finally, Truist Financial lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th.

Read Our Latest Analysis on EW

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $89.15 on Wednesday. The stock has a market capitalization of $51.33 billion, a P/E ratio of 51.23, a P/E/G ratio of 2.36 and a beta of 0.87. The company’s fifty day moving average price is $88.05 and its 200 day moving average price is $86.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences has a 1 year low of $74.66 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.67 earnings per share. As a group, equities research analysts anticipate that Edwards Lifesciences will post 3.00 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 5,045 shares of company stock valued at $451,596. 0.31% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Pin Oak Investment Advisors Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $26,000. TrinityBridge Ltd acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $27,000. GK Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $26,000. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $25,000. Finally, RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.

Featured Stories